Trenbolone Enanthate 100mg – Bangkok Pharmaceuticals Steroid in USA

Trenbolone Enanthate History:

 
Slow acting Trenbolone esters were first studied in 1967, during a series of experiments into synthetic anabolic steroids by Roussel-UCLAF.607 Roussel did not specifically investigate Trenbolone Enanthate, although the drug would have remained an obvious possibility once Trenbolone was released given the widespread application of steroid esters (including enanthate) by the 1960’s.

The drug would not see the light of day for many decades, however, and was only first released for commercial sale in 2004. It was introduced by British Dragon, an underground manufacturer. British Dragon would sell it under the trade name Trenabol, in 200 mg/mL strength.

Although it was not for sale through pharmacies nor approved for human or veterinary use, Trenabol was widely distributed throughout the world, and became an extremely popular product with athletes and bodybuilders. Much of this had to do with the fact that it was unique, in that it was one of but a few options for injectable trenbolone that used slow acting esters. At the time of its introduction, Trenbolone Acetate products were by and large the dominant form of Trenbolone, and remain the dominant form of the steroid to this day. Although British Dragon was perhaps the largest and most well known underground steroid manufacturer in the world, the company abruptly collapsed at the end of 2006. The brand has since re-emerged under new ownership. Trenbolone Enanthate continues to be sold by a number of underground labs, though no registered drug company has yet introduced it to a legitimate drug market.

How Supplied:

Trenbolone Enanthate is not available as a prescription drug product.

Structural characteristics:

Trenbolone is a modified form of Nandrolone. It differs by the introduction of double bonds at carbons 9 and 11, which inhibit aromatization (9-ene), increase androgen binding affinity,608 and slows its metabolism. The resulting steroid is significantly more potent as both an anabolic and an androgen than its Nandrolone base. The Trenbolone here is modified with an enanthate ester at the 17-beta hydroxyl group, so that the free steroid is released more slowly from the area of injection.

Side Effects (Estrogenic):

Trenbolone is not aromatized by the body, and is not measurably estrogenic. It is of note, however, that this steroid displays significant binding affinity for the progesterone receptor (slightly stronger than progesterone itself ).609 610 The side effects associated with Progesterone are similar to those of estrogen, including negative feedback inhibition of Testosterone production and enhanced rate of fat storage. Progestins also augment the stimulatory effect of estrogens on mammary tissue growth.

There appears to be a strong synergy between these two hormones, such that Gynecomastia might even occur with the help of progestins, without excessive estrogen levels. The use of an anti-estrogen, which inhibits the estrogenic component of this disorder, is often sufficient to mitigate gynecomastia caused by progestational anabolic/androgenic steroids. Note that progestational side effects are more common when trenbolone is being taken with other aromatizable steroids.

Side effects (androgenic):

Although classified as an anabolic steroid, Trenbolone is sufficiently androgenic. Androgenic side effects are still common with this substance, and may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss.

Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Additionally, the 5-alpha reductase enzyme does not metabolize trenbolone,611 so its relative androgenicity is not affected by finasteride or dutasteride.

Side effects (Hepatotoxicity):

Trenbolone is not c-17 alpha alkylated, and is generally not considered a hepatotoxic steroid; liver toxicity is unlikely. This steroid does have a strong level of resistance to hepatic breakdown, however, and severe liver toxicity has been noted in bodybuilders abusing Trenbolone. Although unlikely, hepatotoxicity cannot be completely excluded, especially with high doses.

Side effects (cardiovascular):

Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism.

Due to its non-aromatizable nature and strong resistance to metabolism, Trenbolone has a moderate to strong (negative) impact on lipid values and atherogenic risk. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.

To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.

Side effects (Testosterone suppression):

All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous Testosterone production. Without the intervention of Testosterone stimulating substances, Testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention. In experimental studies, trenbolone was determined to be approximately three times stronger at suppressing gonadotropins than testosterone on a milligram for milligram basis.

The above side effects are not inclusive. For more detailed discussion of potential side effects.

Administration (men):

Trenbolone Enanthate was never approved for use in humans. Prescribing guidelines are unavailable. Common doses for physique and performance enhancing purposes fall in the range of 150-300 mg per week, which is usually taken for 6-10 consecutive weeks.

This level is sufficient to produce considerable increases in lean muscle mass and strength, which are usually combined with notable fat loss and increased muscle definition. As with all trenbolone injectables, this product is fairly versatile, and can be combined with many other agents depending on the desired results.

Administration (women):

Trenbolone Enanthate was never approved for use in humans. Prescribing guidelines are unavailable.This agent is generally not recommended for women for physique or performance enhancing purposes due to strong androgenic nature and tendency to produce virilizing side effects.

Availability:

Trenbolone Enanthate is currently not a prescription drug product. It is made exclusively by underground and export oriented steroid manufacturers only.

References:

607. J. Mathieu, Proc. Intern. Symp. Drug Res. 1967, p 134. Chem. Inst. Can., Montreal, Canada.
608. Unique steroid congeners for receptor studies. Ojasoo, Raynaud. Cancer Research 38 (1978):4186-98.
609. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. Bauer, Meyer et al. Acta Pathol Microbiol Imunol Scand Suppl 108 (2000):838-46.
610. Unique steroid congeners for receptor studies. Ojasoo, Raynaud. Cancer Research 38 (1978):4186-98.
611. Disposition of 17 beta-trenbolone in humans. Spranger, Metzler. J Chromatogr 564 (1991):485-92.